search
Back to results

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

Primary Purpose

Clostridium Difficile Colitis

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ileal diversion and lavage
total abdominal colectomy
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Clostridium Difficile Colitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult patients >18 years of age
  2. Able to provide informed consent, or presence of a legally authorized representative able and willing to provide informed consent
  3. Candidates for total abdominal colectomy due to severe, complicated FCDC per consulting surgeon and team providing care
  4. Subjects must meet criteria for operative management of FCDC (find in detailed protocol)

Exclusion Criteria:

  1. Children (<18 years of age)
  2. Allergy or hypersensitivity reaction to study medications: Vancomycin, Metronidazole, GoLytely
  3. Intra-operative evidence of colonic perforation
  4. Intra-operative evidence of colonic necrosis
  5. Pregnancy (this will be ruled out by a urine test at the time of indication for surgery)
  6. Prisoners

Sites / Locations

  • Massachusetts General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

total abdominal colectomy

Ileal diversion and lavage

Arm Description

the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy

The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.

Outcomes

Primary Outcome Measures

Mortality
Both groups will be compared using mortality as the primary outcome.

Secondary Outcome Measures

ICU Length of Stay (LOS
14 days
Hospital LOS
1 year
ventilation days
1 year
morbidity
1 year

Full Information

First Posted
September 17, 2011
Last Updated
April 29, 2015
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01441271
Brief Title
Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis
Official Title
Diverting Loop Ileostomy and Colonic Lavage: An Alternative To Total Abdominal Colectomy For The Treatment Of Fulminant Clostridium Difficile Colitis. A Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Terminated
Why Stopped
Numer of eligible patients markedly decreased since the initiation of the study.
Study Start Date
September 2012 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesize that minimally invasive ileal diversion with intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution will clear Clostridium difficile infection resulting in eradication of Fulminant C. difficile colitis (FCDC) while preserving the colon. Furthermore, the investigators hypothesize this will reduce morbidity and mortality compared to total abdominal colectomy.
Detailed Description
Clostridium difficile (C. difficile) affects more than 3 million patients per year in the United States, and is increasing in frequency [2-15]. Approximately 8 % of hospitalized patients are infected with C. difficile [12]. Of these patients 3% - 8% will develop the fulminant disease, defined as C. difficile colitis with significant systemic toxic effects and shock, resulting in need for colectomy or death [2]. Fulminant C. difficile colitis (FCDC) is a highly lethal disease with mortality rates ranging between 12% - 80% [2-6,8-15]. A retrospective study in our own institution identified a 35% mortality rate for FCDC [2]. The indications for surgical management of patients with FCDC are not clearly defined, however most advocate surgical intervention in patients with worsening clinical exams, peritonitis, or patients in shock. Total abdominal colectomy (also called subtotal colectomy) with end ileostomy has been advocated as the operation of choice and has been demonstrated to marginally improve survival compared to non-operative management in these critically ill patients. A total abdominal colectomy has many disadvantages. Most important, mortality rates continue to range from 35-80%. Additionally, total abdominal colectomy (subtotal colectomy) can result in significant morbidity, and many survivors will have a permanent ileostomy. The new treatment option that will be tested in this randomized controlled trial (RCT) may change the standard of care. Based on a small prospective series from Neal and colleagues [1] the investigators propose an alternative surgical approach for the management of FCDC, which may prove a safer and simpler option. Based on the nature of the disease as a bacterial toxin-mediated mucosal inflammatory process with delayed and indirect systemic threats to life, the investigators think that minimally invasive ileal diversion with intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile Colitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
total abdominal colectomy
Arm Type
Active Comparator
Arm Description
the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
Arm Title
Ileal diversion and lavage
Arm Type
Experimental
Arm Description
The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
Intervention Type
Procedure
Intervention Name(s)
Ileal diversion and lavage
Intervention Description
The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
Intervention Type
Procedure
Intervention Name(s)
total abdominal colectomy
Other Intervention Name(s)
subtotal colectomy
Intervention Description
The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
Primary Outcome Measure Information:
Title
Mortality
Description
Both groups will be compared using mortality as the primary outcome.
Time Frame
28 day
Secondary Outcome Measure Information:
Title
ICU Length of Stay (LOS
Description
14 days
Time Frame
during hospitalization
Title
Hospital LOS
Description
1 year
Time Frame
hospitalization
Title
ventilation days
Description
1 year
Time Frame
while in ICU
Title
morbidity
Description
1 year
Time Frame
during hospitalization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients >18 years of age Able to provide informed consent, or presence of a legally authorized representative able and willing to provide informed consent Candidates for total abdominal colectomy due to severe, complicated FCDC per consulting surgeon and team providing care Subjects must meet criteria for operative management of FCDC (find in detailed protocol) Exclusion Criteria: Children (<18 years of age) Allergy or hypersensitivity reaction to study medications: Vancomycin, Metronidazole, GoLytely Intra-operative evidence of colonic perforation Intra-operative evidence of colonic necrosis Pregnancy (this will be ruled out by a urine test at the time of indication for surgery) Prisoners
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc de Moya, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

We'll reach out to this number within 24 hrs